✦ LIBER ✦

G.P.6.01 Establishing the parameters for clinical trials of antisense oligonucleotide therapy in Duchenne muscular dystrophy

✍ Scribed by M. Kinali; V. Arechavala-Gomeza; L. Feng; A. Glover; M. Guglieri; H. Jungbluth; H. Roper; R.M. Quinlivan; D. Hunt; A.M. Manzur; A. Henderson; J. Gosalakkal; K. Hollingsworth; J. Allsop; E. Mercuri; J. Morgan; C. Sewry; V. Straub; K. Bushby; M. Rutherford; F. Muntoni

Book ID: 116793585
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 46 KB
Volume: 18
Category: Article
ISSN: 0960-8966
DOI: 10.1016/j.nmd.2008.06.171

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

T.P.1 02 A phase I/II clinical trial in

T.P.1 02 A phase I/II clinical trial in Duchenne muscular dystrophy using IM and IV delivered antisense oligonucleotides: The MDEX consortium

✍ V. Arechavala; K. Bushby; G. Dickson; I. Graham; M. Kinali; K. Liu; J. Morgan; F 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Use of the dog model for Duchenne muscul

Use of the dog model for Duchenne muscular dystrophy in gene therapy trials

✍ J McC. Howell; S Fletcher; B.A Kakulas; M O'Hara; H Lochmuller; G Karpati 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 49 KB